Xspray Pharma is close to achieving commercialisation, with two FDA decisions expected this summer.
Duni reported a softer Q1, with sales down 5.3% y/y (-1% organic).
Actic's Q1 looks solid and came in in line with our expectations.
Redeye comments on Dynavox’s Q1 report released earlier this morning, which delivered a solid start ...
Vitrolife reported softer revenues relative to our estimates, as we had projected a more modest fx-i...
Inderes delivered Q1 numbers almost perfectly in line with our estimates.
Following the release of the Q1 2026 report, Physitrack's CEO, Henrik Molin, joins us to discuss the...
Redeye returns with a revised forecast following Binero’s Q1’26 trading update, which showed sequent...
Net sales and adjusted EBITA were below consensus in Q1.
Fiskars' Q1 results were strong, driven by the Fiskars business area (BA Fiskars).
We raise adjusted EBITA by 4-6% for 2026E-28E, following the strong margin development in Q1, with a...
Physitrack’s Q1 2026 report confirms that the structural "SaaS-only" reset has successfully protecte...
Redeye comments on Hansa Biopharma's Q4 report. Revenues were SEK35m (SEK66m).
Redeye retains its positive view of Vitec following the Q1 report.
CDON posted a quarter with solid growth of 14% y/y.
* Underlying development looks promising * We raise our '26-'28 EBIT estimates by 3-1% * Share is tr...
* EBITA margin +20bp y-o-y supported by price adjustments * Warehouse move could offset opex inflati...
Careium reported its third consecutive quarter of organic growth, and we expect this momentum to con...
* Segment EBIT broadly in line with estimates * Margin-enhancing initiatives in Decommissioning payi...
Redeye presents its preview of RaySearch’s Q1 2026 results due on April 29.
